已收盘 05-08 16:00:00 美东时间
+0.130
+1.18%
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $25.
05-08 21:29
Zevra Therapeutics shares are trading lower. The company reported its Q1 financ...
05-08 00:50
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.08 by 125 percent. This is a 400 percent increase over losses of $(0.06) per share from the
05-07 05:23
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
今日重点评级关注:HC Wainwright & Co.:维持Altimmune"买入"评级,目标价从12美元升至25美元;BTIG:维持Jade Biosciences"买入"评级,目标价从28美元升至39美元
03-17 11:45
Zevra Therapeutics Inc. shares are trading higher on Monday after it agreed to sell its SDX Portfolio to Commave for $50 million.
03-16 21:26
VYGR飙升21%,Q4亏损收窄及销售额超预期;Figure大涨超20%,进军汽车贷款市场获华尔街唱多;Stagwell涨逾17%,引入AppLovin先进的移动广告平台>>
03-11 16:04
Zevra Therapeutics jumped in Tuesday premarket trading after partnering with GeneDx to expand NPC genetic testing and reporting fourth-quarter earnings and revenue that beat estimates.
03-11 02:45
Gainers Zevra Therapeutics (NASDAQ:ZVRA) stock moved upwards by 20.6% to $11.0...
03-10 05:05
Zevra Therapeutics shares are trading higher after the company reported better-...
03-10 04:14